| - [| 7} |
|-----|--------|
| - [| } |
| - 1 | ł |

PTOISBURA (16 88 Approved for use brough 16/01/80 CMB 0851-MOT Paleot and Trademock Office: U.S. CEPARTMENT OF OCKENERCE

| ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | inder the Pagersand Raduction Act of 1916, no persons are required to respond to a collection of information w Substitute for form 1449A/PTO | | | Complete if Known | | |
|--|---|-------|---|------------------------|-------------------|--|
| | | ATEME | TION DISCLOSURE NT BY APPLICANT Try sheets as necessary) | Application Number | 10/561,829 | |
| | | | | Filing Date | December 21, 2005 | |
| | | | | First Named Inventor | Shaharyar Khan | |
| | | | | Group Art Unit | 1636 | |
| | | | | Examiner Name | Kimberly A. Makar | |
| Sheet | 1 | af | 2 | Attorney Docket Number | GNC 0001 | |

| Examiner's I | Cite | OTHER ART NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the | |
|--|-------------|--|--------------------|
| initials* | No. | item (book, magazine, journal, serial, symposium, safaiog, etc.), date, page(s), volume-issue number(s), publisher, city amifor country where published | , |
| - | | BAYONA-BAFALUY, "Rapid directional shift of mitochondrial DNA heteroplasmy in animal fissues by a mitochondrially targeted restriction endonuclease," Proc. Natl. Acad. Sci. U S A. 102(40):14392-7(2005). | |
| | | D'SOUZA "Gene therapy of the other genome: the challenges of treating mitochondrial DNA defects" <i>Pharm Res.</i> 24(2):228-38(2007). | ••••• |
| *************************************** | ********** | DEL GAIZO, "A novel TAT-mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta," Mol. Ther. 7(6):720-30(2003). | ******* |
| | | FLIERL, "Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid," Mol. Ther. 7(4):550-7(2003). | |
| abilita a ang Panting an ang Pa | | KHAN, "Development of mitochondrial gene replacement therapy," J. Bioenergetics and Biomembranes 36L387- 393(2004). | . To be the to be |
| | | MALIGA, "Plant Biotechnology 2007: all three genomes make contributions to progress" Current Opinion in Biotech. 18:97-99(2007). | |
| | *********** | MURPHY, "Selective Targeting of Bioactive Compounds to Mitochondria," Trends in Biotech, 15(8):326-30(1997). | n 197 gdq hydadigi |
| *************************************** | | SEIBEL, "Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA diseases," <i>Nucleic Acids</i> Res. 23(1):10-17(1995). | |
| | | SHORE, "Import and Insertion of proteins into the mitochondrial outer membrane" Eur. J. Biochem. 227:9-18(1995) | بالمحادث المادية |
| والدائدة والمتحددة والمتحد | | SLOOTS, "Recombinant derivatives of the human high-mobility group protein HMGB2 mediate efficient nonviral gene delivery" FEBS 272:4221-4236(2005). | |
| *************************************** | | SRIVASTAVA, "Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease," Hum. Mol. Genet.10(26):3093-9(2001). | |

| ************ | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | M 3 AWY 2 A A A S A C A A C A A C A A C A A C A A C A A C A A C A A C | |
|---|--|---|------|
| Evaniner's | | Interchional atest | |
| Transmission of | 1 | rate optimization | |
| Charatura | | | |
| Soldware 1 | | | |
| *************************************** | | | **** |

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Tradement Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with riskl communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ² Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). ³ For Japanesse patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Transfation is attached.

| PT(XSB09A (10-96 |
|---|
| Approved for use through 16/31/99. CMB 6661 6031 |
| Parent and Tractement Officer U.S. DEPARTMENT OF COMMERCE |

| United the Paperwork Reduction Act of 1995, no parametrization to respond to a posterior of information of Substitute For form 1449A/PTO | Complete if Known | | |
|--|------------------------|-------------------|--|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | Application Number | 10/561,829 | |
| | Filing Date | December 21, 2005 | |
| | First Named Inventor | Shaharyar Khan | |
| | Group Art Unit | 1636 | |
| | Examiner Name | Kimberly A. Makar | |
| Sheet 2 of 2 | Attorney Docket Number | GNC 0001 | |

| | | OTHER ART - NON PATENT LITERATURE DOCUMENTS | |
|---|-------------|--|----|
| Examiner's Initials' | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | ް. |
| | | TANAKA, "Gene therapy for mitochondrial disease by delivering restriction endonuclease Smal into mitochondria," <i>J. Biomed, Sci.</i> 9(6 Pt 1):534-41(2002). | |
| | | VESTWEBER, "DNA-protein conjugates can enter mitochondria via the protein import pathway," Nature 338(6211):170- 2(1989). | |
| | ***** | | |
| | | | |
| ······································ | **** | | |
| 4422341344444444444444 | ~~~ | | |
| | | | |
| ****************************** | | | |
| ****************************** | | | |
| *************************************** | | | |
| | | | |

| Examiner's | 1831 | Date Considered | ********** |
|------------|-------------------------------|-----------------|------------|
| Signature | /Qian Janice Li/ (10/02/2009) | | |

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Petent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not classian is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Occuments. ² Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible ⁵ Applicant to place a check mark here if English language Translation is attached.